|Mr. Bart Filius M.B.A., MBA||Pres, COO & Member of Management Board||822.94k||N/A||1970|
|Dr. Andre Hoekema||Chief Bus. Officer & Member of Management Board||579.84k||N/A||1957|
|Dr. Walid Abi-Saab||Chief Medical Officer & Member of Management Board||684.93k||N/A||1965|
|Mr. Michele Manto M.B.A.||Chief Commercial Officer & Member of Management Board||792.4k||N/A||N/A|
|Dr. Paulus A. Stoffels M.D., Ph.D.||CEO, Chairman & Member of Management Board||N/A||N/A||1962|
|Ms. Elizabeth Goodwin||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Sofie Van Gijsel||Head of Investor Relations||N/A||N/A||N/A|
|Marieke Vermeersch||Head of Corp. Communication||N/A||N/A||N/A|
|John Montana||Managing Director of Argenta||N/A||N/A||N/A|
|Ms. Chantal Tasset||Head of Devel.||N/A||N/A||N/A|
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Galapagos NV’s ISS governance QualityScore as of 1 June 2022 is 9. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 9; Compensation: 10.